We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




New Interdisciplinary Research Center Targets the Microbiome

By LabMedica International staff writers
Posted on 19 Nov 2014
Print article
Image: Clostridium difficile (shown here) is a bacterium in the intestines that has been successfully treated through microbiome manipulation (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Image: Clostridium difficile (shown here) is a bacterium in the intestines that has been successfully treated through microbiome manipulation (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
An interdisciplinary research center has been established to promote studies on the microbiome, the many communities of microorganisms living within the human body, and its relation to human health and disease.

The Center for Microbiome Informatics and Therapeutics (CMIT) is a New England (USA) regional center to advance the science of the human microbiome and the treatment of conditions and diseases associated with an altered microbiome. Located at the Massachusetts Institute of Technology (Cambridge, USA), with co-directors from the Massachusetts Institute of Technology and Massachusetts General Hospital (Boston, USA), the center is dedicated to fostering and supporting a research ecosystem involving the participation of hospitals, other universities, and research institutes in the region. The center is being launched with an initial 25 million USD expendable budget over five years, and the first requests for proposals will be released in January 2015.

The center has three core functions: to advance the field by funding research proposals; to help individual research projects proceed more efficiently through shared services, such as a regional sample facility or support for regulatory compliance; and to draw new talent to microbiome research by promoting the field within the academic community. The center focuses on supporting the intersection of research, clinical practice, computational biology, and engineering.

One of the center co-directors, Dr. Ramnik Xavier, chief of gastroenterology at Massachusetts General Hospital, said, “Molecular biologists, microbiologists, and cell biologists seek to understand microbe/microbe and microbe/host cell function and communication. Immunologists, geneticists, and genomics researchers drive progress. To this wealth of information, clinicians contribute patient-based insights and gain potential targets for therapeutics. We want this center to be a convening hub for strengths that are distributed across disciplines and throughout different institutions in the New England region.”

Related Links:

Massachusetts Institute of Technology
Massachusetts General Hospital


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.